If I stop taking semaglutide, do the heart benefits go away?

The weight loss does largely reverse when semaglutide is discontinued, the STEP-4 extension study confirmed this, with patients regaining approximately two-thirds of lost weight within one year of stopping. Because a significant portion of the cardiovascular benefit in SELECT is attributable to the metabolic changes accompanying weight loss (reduced visceral fat, lower blood pressure, improved insulin sensitivity), those benefits are likely to diminish with weight regain.

The parallel to statins is directly relevant here: statins also produce lipid rebound when discontinued, and nobody argues that this means statins should not be prescribed. For patients with established cardiovascular disease whose risk-benefit ratio clearly favors ongoing treatment, semaglutide should be considered a maintenance therapy, not a course. The analogy holds: you do not stop your blood pressure medication when your blood pressure normalizes on treatment. The normalization is the drug working, not evidence that you no longer need it. For men who achieve meaningful cardiovascular risk reduction on semaglutide, the case for indefinite treatment is often clear and well-supported. (Rubino et al., NEJM, 2021)

Cardiologist's calibrated position, Solid (1) for weight regain with discontinuation. Promising (2) for the benefit-maintenance rationale for indefinite treatment in high-risk patients.

What to do: Treat any decision to stop semaglutide as a clinical decision that warrants a cardiovascular risk recalculation with your cardiologist, not a personal convenience choice.

For the full picture, read The Drug That Surprised Cardiologists.